Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;28(4):400-4.
doi: 10.1089/aid.2011.0240. Epub 2011 Sep 27.

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide

Morgane Rolland  1 , Peter Gilbert
Affiliations

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide

Morgane Rolland et al. AIDS Res Hum Retroviruses. 2012 Apr.

Abstract

Since the RV144 vaccine combination showed efficacy in a Phase III trial, it provides an opportunity to generate hypotheses about the immune responses necessary for protection against HIV-1 infection, and these results could help devise vaccine candidates with higher efficacy. Here we describe how researchers can determine the correlates of immune protection for an HIV/AIDS vaccine, particularly in the context of the RV144 trial, and we discuss the terminology used to describe correlates and surrogates.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Power to detect a normally distributed correlate of risk in RV144.
See this image and copyright information in PMC

References

    1. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. 1989;8(4):431–440. - PubMed
    1. Frangakis CE. Rubin DB. Principal stratification in causal inference. Biometrics. 2002;58(1):21–29. - PMC - PubMed
    1. Qin L. Gilbert PB, et al. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis. 2007;196(9):1304–1312. - PubMed
    1. Plotkin SA. Vaccines: Correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401–409. - PubMed
    1. Borgan O., et al. Exposure stratified case-cohort designs. Lifetime Data Anal. 2000;6(1):39–58. - PubMed

Publication types